News and Press Releases

Treovir Announces Opening of G207 Phase 2 Clinical Trial in Children with Recurrent Brain Tumors

4 December 2024 -- Alabama, US -- Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in pediatric brain tumor patients. G207...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: December 4, 2024

Epsilogen announces initiation of Phase Ib trial of MOv18 IgE

Proof-of-concept study to evaluate the safety, tolerability and efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer 3 December 2024 -- London, UK -- Epsilogen, the global leader in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 3, 2024

Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell disease FRONTIER4 interim phase 3 results evaluating safety profile and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2024

Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor 3 December 2024 -- Hong Kong, Shanghai and New Jersey, US — HUTCHMED (China) and Innovent Biologics, Inc...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2024

48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Puma Biotechnology Announces Initiation of ALISCATM-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

20 November 2024 -- California, US -- Puma Biotechnology, Inc, a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCATM-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 20, 2024

Los Angeles, California 424-248-6500 Main

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Eight participants achieved HBsAg loss at any time Two participants met criteria for functional cure Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. 15 November 2024 -- Oxford,...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: November 15, 2024

Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance

Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes 11 November 2024 -- Strasbourg, France -- AdipoPharma, a biotech company headquartered in France with offices in the US...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2024

Nextmed, Bâtiment eXplora (Bureau A203) 2 rue Marie Hamm 67000 Strasbourg France

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

Zero refusals to file and a SOUL mindset helped solidify the honor 8 November 2024 -- Michigan, US -- MMS, a leading data and regulatory focused clinical research organization (CRO),...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 8, 2024

6880 Commerce Blvd. Canton, MI 48187 USA

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma

If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: November 8, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses Our innovative decentralized cell therapy...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 5, 2024

Galapagos NV Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium

NorthWest EHealth (NWEH) announces a pilot to test a new model for finding and recruiting participants for clinical trials using the Clinical Practice Research Datalink

The pilot aims to speed up the process for safely and securely finding participants for UK clinical trials, improving efficiencies and opportunities for people to take part in research and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 5, 2024

2nd Floor Bright Building Manchester Science Park Pencroft Way Manchester M15 6GZ

Loftware and Signant Health Announce Availability of Integrated Clinical Supplies Labeling Solution

Automates to improve speed, enable compliance, and support scalability 31 October 2024 -- New Hampshire, US -- Loftware, the global leader in Enterprise Labeling and Artwork Management solutions, and Signant Health, the leader in...

Category: Clinical Trials, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: October 31, 2024

249 Corporate Dr, Portsmouth, NH 03801

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant...

Category: Clinical Trials, Drug Discovery
Posted: October 24, 2024

DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible

Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and lenalidomide maintenance showed a 58 percent...

Category: Drug Discovery
Posted: October 23, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

BioPharma Industry Excited about the early use of AI in clinical trials

Experts discuss the long road for complete AI-led transformation at Indegene Digital Summit 202421 October 2024 -- New Jersey, US, and London, UK -- Clinical development experts from Novartis, GSK,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 21, 2024

Indegene, Inc. 150 College Rd W Suite 104 Princeton NJ 08540